Every Form 4 that P3 Health Partners Inc. Warrant (PIIIW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PIIIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PIIIW filings page.
Hudson Vegas Investment SPV, LLC, a 10% owner of P3 Health Partners Inc., redeemed 100,000 P3 LLC Units of P3 Health Group, LLC for 100,000 shares of Class A Common Stock on a one-for-one basis. In connection with this redemption, an equal number of shares of Class V Common Stock were forfeited for no consideration.
After these transactions, Hudson Vegas Investment SPV, LLC reported 729,651 P3 LLC Units and 729,651 shares of Class V Common Stock remaining, and 100,000 shares of Class A Common Stock held directly. The P3 LLC Units are redeemable at any time for either newly issued Class A shares on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock, and they do not expire. Hudson Vegas Investment Manager, LLC and Daniel Straus may be deemed to share voting and dispositive power over these securities but disclaim beneficial ownership beyond any pecuniary interest.
Hudson Vegas Investment SPV, LLC, a 10% owner of P3 Health Partners Inc., reported three open-market sales of Class A Common Stock on 2026-08-10 totaling 50,000 shares. The sales used weighted average prices, with transaction price ranges from $13.00–$13.61, $16.00–$16.24, and $16.25–$17.24. Hudson Vegas Investment SPV, LLC is the direct beneficial owner; Hudson Vegas Investment Manager, LLC and Daniel Straus may be deemed to share voting and dispositive power but each disclaims beneficial ownership except to the extent of any pecuniary interest.
P3 Health Partners Inc. large shareholder Hudson Vegas Investment SPV, LLC converted 50,000 P3 LLC Units into 50,000 shares of Class A Common Stock on a one-for-one basis. In connection with this redemption, an equal 50,000 shares of Class V Common Stock were forfeited for no consideration.
After the transactions, Hudson Vegas Investment SPV, LLC held 829,651 P3 LLC Units and 829,651 shares of Class V Common Stock, together with 50,000 shares of Class A Common Stock directly. Earlier, on April 11, 2025, the company and P3 LLC effected coordinated 1-for-50 reverse stock splits, and all reported amounts reflect those adjustments.
P3 Health Partners Inc. reported that its Chief Financial Officer, Leif Elliott Pedersen, received a grant of stock options covering 30,000 shares of Class A common stock. The options have an exercise price of $3.5479 per share, become exercisable on May 8, 2030, and expire on May 8, 2036. Following this award, Pedersen holds stock options for a total of 45,000 shares, reflecting a routine compensation-related equity grant rather than an open-market purchase or sale.
P3 Health Partners Inc. director filed an amended insider trading report updating their share holdings after receiving a new equity grant. The director was granted 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 under the company’s 2021 Incentive Award Plan, at a price of $0 as this is an equity award. Each RSU represents one share of Class A common stock and will vest at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amendment corrects the number of shares beneficially owned to reflect the company’s 1-for-50 reverse stock split effective April 11, 2025, and to include certain indirectly owned securities. Following the correction, the director beneficially owns 6,331 Class A shares directly and 17,192 Class A shares indirectly through G&K Investment Holdings LLC, over which the director has voting and dispositive power.
P3 Health Partners Inc. director reports updated stock grant details. A director received 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, reflecting a standard equity award for board service. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date. After this grant, the director beneficially owns 6,331 Class A common shares directly.
This is an amended insider filing correcting the number of securities shown in Column 5 of Table I. The prior filing had inadvertently used the pre–reverse stock split amount instead of the post–split figure following the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is made solely to fix that post–split beneficial ownership number.
P3 Health Partners Inc. director reported an updated insider holding following an equity award and corporate action. On 08/06/2025, the director received 4,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU converts into one Class A share and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date.
The amended filing corrects the number of Class A shares beneficially owned after the company’s 1‑for‑50 reverse stock split effective April 11, 2025 and now includes securities held indirectly. Following the correction, the director is shown as beneficially owning 12,662 Class A shares directly and 8,520 Class A shares indirectly through AssetBlue Ventures, LLC, over which the director and Nasrin Thierer have voting and dispositive power.
P3 Health Partners Inc. director reported an equity grant and corrected prior share ownership figures. On 08/06/2025, the director received 2,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU represents one share of Class A common stock and will vest upon the earlier of the company’s 2026 annual stockholder meeting and the one-year anniversary of the grant date.
Following the update, the director is shown as beneficially owning 6,331 shares of Class A common stock directly. The amendment was filed to correct the number of securities beneficially owned after the company’s 1-for-50 reverse stock split, which became effective on April 11, 2025, and is limited to fixing that post-split share count.